Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

This article highlights the development of an antibody targeting CD99 in diffuse midline gliomas (DMG). 1. RNA-seq: We performed bulk RNA sequencing of HSJD-GBM01 cells transduced with H3.3K27M and its paired isogenic H3.3-WT cell lines to find the genes altered due to the transduction with the K27M Mutation compared to isogenic H3-WT controls. 2. RNA-seq: We also performed bulk RNA sequencing of SU-DIPG04 cells transduced with short-hair pin RNA (shRNA) targeting CD99 and with transduced with non-target controls to find the genes altered due the knockdown of CD99 compared to those transduced with non-target controls. Overall design: 1. RNA-seq samples were obtained from HSJD-GBM01 glioblastoma cells transduced with H3.3K27M mutation and isogenic H3-WT controls. 2. RNA-seq samples were obtained from SU-DIPG04 DMG cells transduced with shRNA targeting CD99 and with non-target controls.